--- title: "谷歌 DeepMind 倫敦 AI 藥物研發分拆公司目標估值達 500 億美元" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/301273139.md" description: "谷歌 DeepMind 的分拆公司 Isomorphic Labs 在新一輪融資洽談中尋求高達 500 億美元的估值。繼最近完成 21 億美元的 B 輪融資後，這一估值較此前 175 億美元的估值大幅上升。這家由 Demis Hassabis 爵士領導的倫敦公司旨在到 2026 年底開始臨牀試驗，儘管其尚未在人體上測試候選藥物" datetime: "2026-10-08T12:05:22.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/301273139.md) - [en](https://longbridge.com/en/news/301273139.md) - [zh-HK](https://longbridge.com/zh-HK/news/301273139.md) generator: "portal-rs" --- # 谷歌 DeepMind 倫敦 AI 藥物研發分拆公司目標估值達 500 億美元 Thursday 08 October 2026 1:05 pm Add as a preferred source on Google Isomorphic Labs is targeting its first clinical trials by the end of 2026 London-based AI drug discovery firm, Isomorphic Labs, is reportedly seeking a valuation of up to $50bn (£37bn) in fresh funding talks, just five months after raising $2.1bn from investors. The Google DeepMind spinout, led by Nobel Prize-winning scientist Sir Demis Hassabis, is in early discussions to raise new capital at a valuation of at least $40bn, according to Bloomberg. The figure could climb as high as $50bn, although negotiations remain early and no agreement has been reached. The potential valuation would mark a sharp rise from the roughly $17.5bn previously attached to the company, as investors pour money into businesses promising to use AI to transform drug development. Founded in London in 2021, Isomorphic Labs uses AI to design potential medicines, building on DeepMind’s AlphaFold technology, which predicts protein structure. The company is developing treatments for cancer and immune disorders, while also working with pharmaceutical giants including Eli Lilly, Novartis and Johnson and Johnson. Its technology aims to reduce the time and cost of discovering new drugs by predicting how molecules will interact with biological targets before testing them in laboratories. However, despite attracting billions in investment, Isomorphic has yet to test its own drug candidates in humans. The company is targeting its first clinical trials by the end of 2026, a key milestone in demonstrating whether its AI technology can translate into viable medicines ## London AI firm attracts billions in funding The reported talks follow a $2.1bn Series B funding round in May, backed by investors including Alphabet, Thrive Capital and the UK Sovereign AI Fund. That followed a $600m raise in March 2025, bringing its disclosed external funding to about $2.7bn. Alphabet remains the company’s majority owner, while Hassabis continues as chief executive after stepping back from his day-to-day leadership role at DeepMind in August to become its chairman and Alphabet’s chief scientist. The latest funding discussions also come as Isomorphic expands its role in a wider push to use AI in biological research. On Wednesday, the company joined Google DeepMind and Meta in committing a combined $300m to a new initiative to develop AI models capable of predicting how human cells behave. The project, led by research organisation Biohub and supported by US government agencies, forms part of a broader $1.8bn effort to build so-called virtual cells that could eventually allow scientists to test potential treatments digitally. For Britain, Isomorphic’s rapid rise offers another potential heavyweight in London’s AI sector, which has attracted growing international investment. UK AI companies raised £8.3bn in 2025, while Isomorphic was recently named among Britain’s leading AI businesses in Barclays’ AI 100 ranking. But the company’s soaring potential valuation also highlights the gap between investor enthusiasm for AI-driven medicine and its commercial reality. While AI firms promise to slash the cost and time required to develop drugs, few have reached human trials, and none has yet brought an AI-discovered medicine to market. ### 相關股票 - [JNJ.US](https://longbridge.com/zh-HK/quote/JNJ.US.md) - [LLY.US](https://longbridge.com/zh-HK/quote/LLY.US.md) - [NVS.US](https://longbridge.com/zh-HK/quote/NVS.US.md) - [ELIL.US](https://longbridge.com/zh-HK/quote/ELIL.US.md) - [ELIS.US](https://longbridge.com/zh-HK/quote/ELIS.US.md) - [GGLL.US](https://longbridge.com/zh-HK/quote/GGLL.US.md) - [GGLS.US](https://longbridge.com/zh-HK/quote/GGLS.US.md) - [GOIB.US](https://longbridge.com/zh-HK/quote/GOIB.US.md) - [GOOL.US](https://longbridge.com/zh-HK/quote/GOOL.US.md) - [GOOW.US](https://longbridge.com/zh-HK/quote/GOOW.US.md) - [GOOY.US](https://longbridge.com/zh-HK/quote/GOOY.US.md) - [GOU.US](https://longbridge.com/zh-HK/quote/GOU.US.md) - [LLYX.US](https://longbridge.com/zh-HK/quote/LLYX.US.md) - [LLYZ.US](https://longbridge.com/zh-HK/quote/LLYZ.US.md) - [NOT.DE](https://longbridge.com/zh-HK/quote/NOT.DE.md) - [GOOG.US](https://longbridge.com/zh-HK/quote/GOOG.US.md) - [META.US](https://longbridge.com/zh-HK/quote/META.US.md) ## 相關資訊與研究 - [不用 Flash 命名，谷歌發佈 Gemini 4 Hydrogen：幻覺減少 5 倍，速度翻倍](https://longbridge.com/zh-HK/news/305371744.md) - [滙豐銀行表示現在是買入字母股的良機](https://longbridge.com/zh-HK/news/305364096.md) - [諾華製藥發佈第三季度影響力與可持續發展更新](https://longbridge.com/zh-HK/news/305047961.md) - [谷歌最新搜索升級承諾更好地回答您最複雜的問題](https://longbridge.com/zh-HK/news/305363383.md) - [谷歌開啓 Gemini 驅動的智能眼鏡預售](https://longbridge.com/zh-HK/news/305335543.md) --- > **免責聲明: 本文僅供參考，不構成任何投資建議。**